These authors presented their experience with the Memokath stent over an 8-year period . The IPSS was assessed in only a third of the patients initially, with many fewer assessed 2 years after stent insertion, and only two assessed at 7 years. In the 25 patients who were demented, the IPSS was scored by their carers; the validity of these scores is questionable. The stent requires hot water (55°C) for correct positioning; this must have been a problem in the 25 demented patients. There are no details of the few patients who underwent urodynamics. Stent position and residual volumes were checked every 6 months by ultrasonography; it would have been interesting to know if there was any significant change in the residual volumes after stent insertion in those not in retention. Curiously, no patient with prostate cancer had any tissue ingrowth. This is certainly a difficult group of patients to treat and they usually are left with a long-term catheter and all its associated problems . The Memokath would certainly be a useful addition to any urologist's options in treating this group of patients.